Clinical Research Directory
Browse clinical research sites, groups, and studies.
Parenteral Ascorbic Acid Repletion in TransplantatIon
Sponsor: University of Wisconsin, Madison
Summary
A single-center, randomized, double-blinded placebo-controlled trial is proposed to investigate administration of supraphysiologic doses of ascorbic acid (vitamin C, AA) to patients undergoing liver transplantation. Participants randomized to the intervention group will receive intravenous (IV) AA 1500 mg every 6 hours for 48 hours. Participants randomized to the control group will receive a saline placebo. The primary study outcome will be a change in the Sequential Organ Failure Assessment (SOFA) score from baseline to three days after the first dose of drug (dSOFA3). Secondary outcomes will include total vasopressor dose in norepinephrine equivalents, 30-day and 1-year mortality, and serum AA levels.
Official title: Parenteral Ascorbic Acid Repletion in TransplantatIon (PARTI): A Randomized, Double-Blinded, Placebo-Controlled Trial
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
90
Start Date
2026-09
Completion Date
2032-03
Last Updated
2026-07-01
Healthy Volunteers
No
Conditions
Interventions
Ascorbic acid
Intravenous vitamin C
Placebo
Normal Saline
Locations (1)
University of Wisconsin Hospital and Clinics
Madison, Wisconsin, United States